Edesa Biotech, Inc.EDSANASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank57
5Y CAGR-33.1%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-33.1%/yr
Long-term compound
Percentile
P57
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 27.30% |
| 2024 | -39.89% |
| 2023 | -64.05% |
| 2022 | -25.70% |
| 2021 | 439.04% |
| 2020 | 203.66% |
| 2019 | -47.47% |
| 2018 | 5.78% |
| 2017 | 14.11% |
| 2016 | 67.99% |